The company is on schedule for its first 6-month readout in 2026 from its pivotal Phase 3 study enrolling 760 Alzheimer's patients, with dual evaluation of symptomatic efficacy at 6 months and disease-modifying response at 18 months. Annovis is also launching an Open-Label Extension study for Parkinson's disease in January 2026 targeting 500 patients, positioning the company for potential regulatory pathway advancement.
Cyborg Score Rationale
Analysts rate the company as Strong Buy with a consensus rating from 2 analysts, though the company faces significant financing risks and pipeline challenges in neurodegenerative disease development. Clinical progress appears strong with 2026 data catalysts, but execution risks remain material.
Top Insights
All 84 U.S. Phase 3 sites are fully activated with 25% enrollment completion toward 760 patients; first participants hit 6-month milestone
Open-Label Extension study for Parkinson's disease launching January 2026 with 500-patient enrollment target across U.S. sites for 36-month treatment period
Company faces significant financing risks due to limited cash runway, potentially necessitating dilutive capital raising
Buntanetap is designed to address Alzheimer's and Parkinson's disease as a synthetically produced, orally administered, brain-penetrant small molecule
Named Competitors
Lecanemab — Amyloid-targeting monoclonal antibody for early Alzheimer's disease
Donanemab — Next-generation anti-amyloid antibody for Alzheimer's disease
Various PD therapies — Parkinson's disease symptomatic and disease-modifying treatments
Recent Developments
(January 2026) Open-Label Extension study for Parkinson's disease launched with 500-patient enrollment target and FDA NDA readiness focus
(November 2025) All 84 Phase 3 Alzheimer's sites fully activated with 25% enrollment completion; first patients completed 6-month milestone
(December 2025) Phase 3 Alzheimer's symptomatic efficacy data expected in H2 2026
Open the full interactive Annovis Bio, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.